-
In 2022, which segments of the pharmaceutical industry are worthy of seizing opportunities?
Time of Update: 2022-01-25
The fund manager of China Asset Management believes that in the entire investment strategy, it is worth paying attention to these pharmaceutical companies with pricing power, and is optimistic about 4 directions: First, biomedicine at the manufacturing end and upstream equipment, reagents and consumables of biomedicine Second, the field of medical consumer goods, such as specialized medical services, consumer medical consumables and traditional Chinese medicine products, etc.
-
Dong'e Ejiao Chairman Han Yuewei and President Gao Dengfeng resign
Time of Update: 2022-01-25
Gao Dengfeng applied for his resignation as the company's president and legal representative .
Gao Dengfeng will continue to serve as a director of the tenth board of directors of the company .
-
120 million US dollars to introduce!
Time of Update: 2022-01-25
In September 2021, Mirum announced that the FDA approved maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year and older .
-
The pharmaceutical and biological industry is showing two major trends
Time of Update: 2022-01-25
On the one hand, with the improvement of people's living standards, people's demand for different products in the field of pharmaceutical consumption is also increasing, making the pharmaceutical and biological industry track gradually diversified .
-
In 2022, personnel changes in pharmaceutical companies are becoming more frequent
Time of Update: 2022-01-25
On January 6, Buchang Pharmaceutical announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and would not hold any position in the company after resignation.
-
Ascletis submits clinical application for oral PD-L1 small molecule inhibitor in the United States
Time of Update: 2022-01-25
According to Ascletis in a press release, ASC61 is a potent and highly selective oral PD-L1 small-molecule inhibitor developed by the company.
-
8 departments jointly issued the "14th Five-Year Plan" National Drug Safety and Promotion of High-quality Development Plan
Time of Update: 2022-01-25
It was learned on December 30 that a few days ago, the State Food and Drug Administration and other 8 departments jointly issued the "14th Five-Year Plan for National Drug Safety and Promotion of Hig
-
Harmonicare Pharmaceuticals completes the first interim analysis of the Phase III clinical trial of Tenacept
Time of Update: 2022-01-24
On January 12, Harbin Pharmaceutical announced that the Phase III registration clinical trial of its new drug ternacept (HBM9036) in China has completed the first interim analysis .
Tenacept (HBM9036) is a globally innovative tumor necrosis factor (TNF) receptor-1 fragmented drug for adults with moderate to severe dry eye (DED) .
-
Key Points of Executive Speeches of 15 Pharmaceutical Giants at JPM Conference
Time of Update: 2022-01-24
Executives said BMS' new product portfolio could generate $25 billion or more in revenue by 2029, while the company is planning to bring seven products to market in mid-to-late development stages .
-
Accelerating the launch of innovative drugs in China, risks and benefits coexist
Time of Update: 2022-01-24
This drug is a new generation of small molecule STING agonists, and no drug with the same target has been approved for marketing .
-
JPM Conference: WuXi AppTec's R&D personnel account for over 80% of the total number of Cinda employees over 6,000
Time of Update: 2022-01-24
In addition, domestic companies such as BeiGene and Innovent Bio also disclosed the latest team numbers at the Morgan Conference .
Baiji's R&D team has more than 3,700 people, including 800 overseas, achieving CRO-free; the sales team has more than 3,400 people, including 3,200 domestic and 200 overseas .
-
At the beginning of the new year, multinational pharmaceutical companies have started the road of "buy, buy, buy"
Time of Update: 2022-01-24
In order to increase the scale of the industry, reduce homogeneous competition, and expand the enterprise, pharmaceutical companies will continue to enrich the product pipeline and improve the research and development strength of innovative drugs .
-
The "14th Five-Year" National Eye Health Plan was issued to focus on the prevention and treatment of eye diseases and the rehabilitation of low vision
Time of Update: 2022-01-24
During the "Thirteenth Five-Year Plan" period, the prevention and control of myopia in children and adolescents was included in the government performance assessment, forming a good atmosphere of "government leadership, department cooperation, expert guidance, school education, and family attention", and ophthalmic medical and health services developed rapidly.
-
The collection of proprietary Chinese medicines is frequent, and the market "shuffle" may speed up
Time of Update: 2022-01-24
However, it is worth noting that, judging from the 19 provinces, autonomous regions and municipalities led by Hubei Province some time ago, the 19 provinces, autonomous regions and municipalities in the alliance opened bids for the centralized procurement of Chinese patent medicines, and the average price dropped by 42.
-
The boundaries of physician practice have been broken, can we recreate the major varieties of traditional Chinese medicine in the new era?
Time of Update: 2022-01-24
There are more than 10 gastric medicine products with sales of more than 100 million yuan in the terminal Chinese patent medicine market of public medical institutions in China.
-
The State Food and Drug Administration issued a revised instruction manual for cimetidine injection preparations
Time of Update: 2022-01-24
5. Provincial drug regulatory authorities shall urge the drug marketing authorization holders of the above-mentioned drugs within the administrative region to do a good job in revising the corresponding instructions and replacing the labels and instructions as required, and strictly investigate and punish violations of laws and regulations in accordance with the law .
-
Flunarizine Hydrochloride Capsules, a wholly-owned subsidiary of Zhendong Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2022-01-24
On the morning of January 14, Zhendong Pharmaceutical announced that its wholly-owned subsidiary Anxin Bio had received the "Approval Notice for Supplementary Drug Application" issued by the State Drug Administration, and that Flunarizine Hydrochloride Capsules had been approved as a generic drug.
-
In 2022, the AI pharmaceutical track is still hot!
Time of Update: 2022-01-24
The two companies will leverage Absci's AI-driven drug innovation platform for drug development; Sanofi announced a research collaboration license agreement of up to $5.
-
Gansu improves the level of drug security: new anti-tumor drugs will continue to enter medical insurance
Time of Update: 2022-01-24
At the meeting, Yang Wenbin, director of the Planning, Finance, Policy and Regulation Division of the Gansu Provincial Medical Security Bureau , said in response to reporters' questions that it is necessary to improve the level of treatment for major diseases and the guarantee of medication for special groups, innovate the way of negotiating the guarantee of drug supply, and establish and improve "dual-channel" management.
-
Under the AI pharma boom, the layout of pharmaceutical machine companies in this track will continue to accelerate
Time of Update: 2022-01-24
Under the AI pharma boom, pharmaceutical machine companies will accelerate their deployment in this track (Photo source: PharmaNet) Major pharmaceutical companies are accelerating the development of AI drugs Recently, Amgen announced that it has reached a research cooperation agreement with Generate Biomedicines .
